Amneal Pharmaceuticals Total Revenue

The latest total revenue for AMRX is $2.4B as of June 2026. That compares with $2.9B in the prior-year period — down 16.0% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Amneal Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, AMRX's total revenue moved from $2.9B to $2.4B — a 16.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Amneal Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, AMRX currently prints $2.4B for total revenue, while the sector average sits near $110B. That is roughly 97.9% below the sector mean. Large gaps often invite a closer look at Amneal Pharmaceuticals's growth, margins, and balance sheet.

A total revenue figure of $2.4B for AMRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting AMRX's total revenue ($2.4B), review year-over-year change from $2.9B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.